litlas
Log inCreate account

Kimmo Porkka

Active 1991–2025

91
Papers
19,219
Citations
63
h-index
91
i10-index

Citations

Citations per year for Kimmo Porkka1979: 4 citations1986: 4 citations1987: 1 citations1993: 1 citations1994: 5 citations1995: 2 citations1996: 8 citations1997: 12 citations1998: 10 citations1999: 24 citations2000: 32 citations2001: 29 citations2002: 38 citations2003: 49 citations2004: 59 citations2005: 48 citations2006: 55 citations2007: 61 citations2008: 48 citations2009: 69 citations2010: 73 citations2011: 71 citations2012: 98 citations2013: 113 citations2014: 100 citations2015: 113 citations2016: 164 citations2017: 155 citations2018: 146 citations2019: 405 citations2020: 478 citations2021: 720 citations2022: 631 citations2023: 639 citations2024: 1,126 citations2025: 535 citations2026: 11 citations1980–1985: no citations, so these years are not shown1988–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,208 citing papers, 24.7% of this breakdownGermany: 630 citing papers, 7.1% of this breakdownItaly: 563 citing papers, 6.3% of this breakdownChina: 531 citing papers, 5.9% of this breakdownUnited Kingdom: 469 citing papers, 5.2% of this breakdownFrance: 456 citing papers, 5.1% of this breakdownFinland: 376 citing papers, 4.2% of this breakdownAustralia: 296 citing papers, 3.3% of this breakdownSpain: 289 citing papers, 3.2% of this breakdownCanada: 282 citing papers, 3.2% of this breakdownNetherlands: 226 citing papers, 2.5% of this breakdownSweden: 214 citing papers, 2.4% of this breakdown
0%24.7%Other 26.9%

Institutions

Fields

  • Medicine70.1%
  • Biochemistry, Genetics and Molecular Biology16.1%
  • Immunology and Microbiology7.1%
  • Computer Science2.1%
  • Materials Science1.8%
  • Engineering0.8%
  • Other2%

Topics

  • Acute Myeloid Leukemia Research12.2%
  • Chronic Myeloid Leukemia Treatments6%
  • Chronic Lymphocytic Leukemia Research4.1%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment3.8%
  • Acute Lymphoblastic Leukemia research3.4%
  • Immune Cell Function and Interaction2.5%
  • Other68%

Coauthors

All papers

Open in search
  1. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

    Authors: Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso‐Ramos, Jörge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström‐Lindberg, Gabriela Hobbs, Ronald Hoffman, Elias Jabbour, Jean‐Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte M. Niemeyer, Olatoyosi Odenike, Seishi Ogawa, Alberto Órfão, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching‐Hon Pui, Jerald P. Radich, Andreas Reiter, Marı́a Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt‐Graeff, Akiko Shimamura, Jorge Sierra, Wendy Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei‐Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi - Blood 2022 cited by 2,693

  2. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

    Authors: Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Andrew H. Wei, Marina Konopleva, Hartmut Döhner, Anthony Letai, Pierre Fenaux, Elizabeth A. Koller, Violaine Havelange, Brian Leber, Jordi Esteve, Jianxiang Wang, Vlatko Pejša, Roman Hájek, Kimmo Porkka, Árpád Illés, David Lavie, Roberto M. Lemoli, Kazuhito Yamamoto, Sung‐Soo Yoon, Jun‐Ho Jang, Su‐Peng Yeh, Mehmet Turgut, Wan‐Jen Hong, Ying Zhou, Jalaja Potluri, Keith W. Pratz - New England Journal of Medicine 2020 cited by 2,771

  3. Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia

    Authors: Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Hartmut Döhner, Christian Récher, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang, Sung‐Soo Yoon, Ofir Wolach, Su‐Peng Yeh, Brian Leber, Jordi Esteve, Jiřı́ Mayer, Kimmo Porkka, Árpád Illés, Roberto M. Lemoli, Mehmet Turgut, Grace Ku, Catherine L. Miller, Ying Zhou, Meng Zhang, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo - American Journal of Hematology 2024 cited by 202

  4. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

    Authors: Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Pau Montesinos, Boris V. Afanasyev, Hervé Dombret, Farhad Ravandi, Hamid Sayar, Jun‐Ho Jang, Kimmo Porkka, Dominik Selleslag, Irwindeep Sandhu, Mehmet Turgut, Valentina Giai, Yishai Ofran, Merih Kızıl Çakar, Aïda Botelho de Sousa, Justyna Rybka, Chiara Frairia, Lorenza Borin, Germana Beltrami, Jaroslav Čermák, Gert J. Ossenkoppele, Ignazia La Torre, Barry Skikne, Keshava Kumar, Qian Dong, C.L. Beach, Gail J. Roboz - New England Journal of Medicine 2020 cited by 424

  5. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia

    Authors: Heikki Kuusanmäki, Aino‐Maija Leppä, Petri Pölönen, Mika Kontro, Olli Dufva, Debashish Deb, Bhagwan Yadav, Oscar Brück, Ashwini Kumar, Hele Everaus, Bjørn Tore Gjertsen, Merja Heinäniemi, Kimmo Porkka, Satu Mustjoki, Caroline A. Heckman - Haematologica 2019 cited by 186

  6. Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Authors: Disha Malani, Ashwini Kumar, Oscar Brück, Mika Kontro, Bhagwan Yadav, Monica Hellesøy, Heikki Kuusanmäki, Olli Dufva, Matti Kankainen, Samuli Eldfors, Swapnil Potdar, Jani Saarela, Laura Turunen, Alun Parsons, Imre Västrik, Katja Kivinen, Janna Saarela, Riikka Räty, Minna Lehto, Maija Wolf, Bjørn Tore Gjertsen, Satu Mustjoki, Tero Aittokallio, Krister Wennerberg, Caroline A. Heckman, Olli Kallioniemi, Kimmo Porkka - Cancer Discovery 2021 cited by 198

  7. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

    Authors: Heikki Kuusanmäki, Olli Dufva, Markus Vähä‐Koskela, Aino‐Maija Leppä, Jani Huuhtanen, Ida Vänttinen, Petra Nygren, Jay Klievink, Jonas Bouhlal, Petri Pölönen, Qi Zhang, Shady Adnan Awad, Cristina Mancebo-Pérez, Joseph Saad, Juho J. Miettinen, Komal Kumar Javarappa, Sofia Aakko, Tanja Ruokoranta, Samuli Eldfors, Merja Heinäniemi, Kim Theilgaard‐Mönch, Ulla Wartiovaara‐Kautto, Mikko Keränen, Kimmo Porkka, Marina Konopleva, Krister Wennerberg, Mika Kontro, Caroline A. Heckman, Satu Mustjoki - Blood 2022 cited by 125

  8. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies

    Authors: Bhagwan Yadav, Tea Pemovska, Agnieszka Szwajda, Evgeny Kulesskiy, Mika Kontro, Riikka Karjalainen, Muntasir Mamun Majumder, Disha Malani, Astrid Murumägi, Jonathan C. Knowles, Kimmo Porkka, Caroline A. Heckman, Olli Kallioniemi, Krister Wennerberg, Tero Aittokallio - Scientific Reports 2014 cited by 369

  9. Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia

    Authors: Hanna Koskela, Samuli Eldfors, Pekka Ellonen, Arjan J. van Adrichem, Heikki Kuusanmäki, Emma Andersson, Sonja Lagström, Michael J. Clemente, Thomas L. Olson, Sari E. Jalkanen, Muntasir Mamun Majumder, Henrikki Almusa, Henrik Edgren, Maija Lepistö, Pirkko Mattila, Kathryn M Guinta, Pirjo Koistinen, Taru Kuittinen, Kati Penttinen, Alun Parsons, Jonathan C. Knowles, Janna Saarela, Krister Wennerberg, Olli Kallioniemi, Kimmo Porkka, Thomas P. Loughran, Caroline A. Heckman, Jaroslaw P. Maciejewski, Satu Mustjoki - New England Journal of Medicine 2012 cited by 766

  10. Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia

    Authors: Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta, Amanda Ranta, Jani Huuhtanen, Minna Suvela, Alun Parsons, Annasofia Holopainen, Anu Partanen, Milla E.L. Kuusisto, Sirpa Koskela, Riikka Räty, Maija Itälä‐Remes, Imre Västrik, Olli Dufva, Sanna Siitonen, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Mika Kontro - Haematologica 2022 cited by 51

  11. Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia

    Authors: Tea Pemovska, Mika Kontro, Bhagwan Yadav, Henrik Edgren, Samuli Eldfors, Agnieszka Szwajda, Henrikki Almusa, Maxim M. Bespalov, Pekka Ellonen, Erkki Elonen, Bjørn Tore Gjertsen, Riikka Karjalainen, Evgeny Kulesskiy, Sonja Lagström, Anna Lehto, Maija Lepistö, Tuija Lundán, Muntasir Mamun Majumder, Jesús M. López Martí, Pirkko Mattila, Astrid Murumägi, Satu Mustjoki, Aino Palva, Alun Parsons, Tero Pirttinen, Maria E. Rämet, Minna Suvela, Laura Turunen, Imre Västrik, Maija Wolf, Jonathan C. Knowles, Tero Aittokallio, Caroline A. Heckman, Kimmo Porkka, Olli Kallioniemi, Krister Wennerberg - Cancer Discovery 2013 cited by 406

  12. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

    Authors: Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Steven Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia‐Manero, Norbert Vey, Martin Wermke, Jeroen Janssen, Rupa Narayan, Sun Loo, Mika Kontro, Oliver G. Ottmann, Purushotham Naidu, Marc R. Pelletier, May Han, Andrew Lewandowski, Na Zhang, Anisa Mohammed, Mikael L. Rinne, Uma Borate, Andrew H. Wei, Natalia Tovar - Blood 2021 cited by 101

  13. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

    Authors: Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Steven Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia‐Manero, Norbert Vey, Martin Wermke, Jeroen J. W. M. Janssen, Rupa Narayan, Shaun Fleming, Sun Loo, Natalia Tovar, Mika Kontro, Oliver G. Ottmann, Purushotham Naidu, Haiying Sun, May Han, Roisin White, Na Zhang, Anisa Mohammed, Catherine Sabatos-Peyton, David P. Steensma, Mikael L. Rinne, Uma Borate, Andrew H. Wei - American Journal of Hematology 2023 cited by 46

  14. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

    Authors: Kimmo Porkka, Perttu Koskenvesa, Tuija Lundán, Johanna Rimpiläinen, Satu Mustjoki, Richard Smykla, Robert A. Wild, Roger Luo, Montserrat Arnán, Benoît Brethon, Lydia Eccersley, Henrik Hjorth‐Hansen, Martin Höglund, Hana Klamová, Håvar Knutsen, Suhag Parikh, Emmanuel Raffoux, Franz Gruber, F. Brito‐Babapulle, Hervé Dombret, Rafael F. Duarte, Erkki Elonen, Ron Paquette, C. Michel Zwaan, Francis Y. F. Lee - Blood 2008 cited by 443

  15. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

    Authors: Bob Löwenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J. Biemond, Olivier Spertini, Edo Vellenga, Laimonas Griškevičius, Lidwine W. Tick, Mojca Jongen‐Lavrencic, Marinus van Marwijk Kooy, Marie-Christiane Vekemans, Walter J. F. M. van der Velden, Berna Beverloo, Lucienne Michaux, Carlos Graux, Dries Deeren, Okke de Weerdt, Joost W. J. van Esser, Mario Bargetzi, Saskia K. Klein, Alain Gadisseur, Peter E. Westerweel, Hendrik Veelken, Michael Gregor, Tobias Silzle, Daniëlle van Lammeren-Venema, Ine Moors, Dimitri Breems, Mels Hoogendoorn, Marie-Cecile J. C. Legdeur, Thomas Fischer, Juergen Kuball, Jan J. Cornelissen, Kimmo Porkka, Gunnar Juliusson, Peter Meyer, Martin Höglund, Bjørn Tore Gjertsen, Jeroen J. W. M. Janssen, Gerwin Huls, Jakob Passweg, Jacqueline Cloos, Peter J.M. Valk, Catharina Van Elssen, Markus G. Manz, Yngvar Fløisand, Gert J. Ossenkoppele - Blood Advances 2021 cited by 66

  16. A tumor-homing peptide with a targeting specificity related to lymphatic vessels

    Authors: Pirjo Laakkonen, Kimmo Porkka, Jason A. Hoffman, Erkki Ruoslahti - Nature Medicine 2002 cited by 493

  17. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

    Authors: Juan Luis Steegmann, Michele Baccarani, Massimo Breccia, Luis Felipe Casado, Valentín García‐Gutiérrez, Andreas Hochhaus, D.-W. Kim, T D Kim, H. Jean Khoury, P. Le Coutre, Jiří Mayer, Dragana Milojković, Kimmo Porkka, Delphine Réa, Gianantonio Rosti, Susanne Saußele, R. Hehlmann, Richard E. Clark - Leukemia 2016 cited by 475

  18. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

    Authors: Mette Ilander, Ulla Olsson‐Strömberg, Heinrich Schlums, Joëlle Guilhot, Oscar Brück, Hanna Lähteenmäki, Tiina Kasanen, Perttu Koskenvesa, S Söderlund, Martin Höglund, Berit Markevärn, Anders Själander, Kourosh Lotfi, Arta Dreimane, Anna Lübking, Elena Holm, Mats Björeman, Sören Lehmann, Leif Stenke, Lotta Ohm, Tobias Gedde‐Dahl, Waleed Majeed, Hans Ehrencrona, Satu Koskela, Susanne Saußele, F-X Mahon, Kimmo Porkka, Henrik Hjorth‐Hansen, Yenan T. Bryceson, Johan Richter, Satu Mustjoki - Leukemia 2016 cited by 247

  19. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

    Authors: Eric K. Rowinsky, Agne Paner, Jesús G. Berdeja, Claudia E. Paba‐Prada, Parameswaran Venugopal, Kimmo Porkka, Joachim Gullbo, Stig Linder, Angelica Loskog, Paul G. Richardson, Ola Landgren - Investigational New Drugs 2020 cited by 101

  20. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

    Authors: Andrés Jerez, Michael J. Clemente, Hideki Makishima, Hanna Koskela, Francis LeBlanc, Kwok Peng Ng, Thomas L. Olson, Bartlomiej Przychodzen, Manuel Afable, Inés Gómez‐Seguí, Kathryn M Guinta, Lisa Durkin, Eric D. Hsi, Kathy L. McGraw, Dan Zhang, Marcin W. Włodarski, Kimmo Porkka, Mikkael A. Sekeres, Alan F. List, Satu Mustjoki, Thomas P. Loughran, Jaroslaw P. Maciejewski - Blood 2012 cited by 418

  21. Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones

    Authors: Aleksandr Ianevski, Kristen Nader, Kyriaki Driva, Wojciech Senkowski, Daria Bulanova, Lidia Moyano‐Galceran, Tanja Ruokoranta, Heikki Kuusanmäki, Nemo Ikonen, Philipp Sergeev, Markus Vähä‐Koskela, Anil K. Giri, Anna Vähärautio, Mika Kontro, Kimmo Porkka, Esa Pitkänen, Caroline A. Heckman, Krister Wennerberg, Tero Aittokallio - Nature Communications 2024 cited by 50

  22. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia

    Authors: Hanna Rajala, Samuli Eldfors, Heikki Kuusanmäki, Arjan J. van Adrichem, Thomas L. Olson, Sonja Lagström, Emma Andersson, Andrés Jerez, Michael J. Clemente, Yiyi Yan, Dan Zhang, Andy Awwad, Pekka Ellonen, Olli Kallioniemi, Krister Wennerberg, Kimmo Porkka, Jaroslaw P. Maciejewski, Thomas P. Loughran, Caroline A. Heckman, Satu Mustjoki - Blood 2013 cited by 296

  23. Patient-tailored design for selective co-inhibition of leukemic cell subpopulations

    Authors: Aleksandr Ianevski, Jenni Lahtela, Komal Kumar Javarappa, Philipp Sergeev, Bishwa Ghimire, Prson Gautam, Markus Vähä‐Koskela, Laura Turunen, Nora Linnavirta, Heikki Kuusanmäki, Mika Kontro, Kimmo Porkka, Caroline A. Heckman, Pirkko Mattila, Krister Wennerberg, Anil K. Giri, Tero Aittokallio - Science Advances 2021 cited by 51

  24. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels

    Authors: Sven Christian, Ján Pilch, Maria E. Åkerman, Kimmo Porkka, Pirjo Laakkonen, Erkki Ruoslahti - The Journal of Cell Biology 2003 cited by 488